Premium
Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease
Author(s) -
Seger Aline D.,
Farrher Ezequiel,
Doppler Christopher E.J.,
Gogishvili Ana,
Worthoff Wieland A.,
Filss Christian P.,
Barbe Michael T.,
Holtbernd Florian,
Shah N. Jon,
Fink Gereon R.,
Sommerauer Michael
Publication year - 2021
Publication title -
movement disorders
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.352
H-Index - 198
eISSN - 1531-8257
pISSN - 0885-3185
DOI - 10.1002/mds.28674
Subject(s) - dopaminergic , parkinson's disease , movement disorders , neuroscience , dopamine , psychology , medicine , disease
Background Motor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain. Objectives The aim of this study is to determine whether putaminal y‐aminobutyric acid (GABA) levels are associated with dopaminergic motor response. Methods We assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra‐high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression. Results In PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response. Conclusions Our findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society